Belgium's Fagron Q1 revenue rises 10.3%, boosted by EMEA, Latin America

Fagron NV

09/04/2026 06:09

Overview

Belgium/Netherlands pharmaceutical compounding firm's Q1 revenue rose 10.3% to €263.4 mln

Organic growth at constant exchange rates (CER) was 3.2%, with all regions contributing positively

Company completed Pharmavit acquisition in the Netherlands, integration progressing as planned

Outlook

Fagron sees FY 2026 organic sales growth at CER in mid- to high-single digits

Company expects FY 2026 REBITDA margin of about 20%, with H2 higher than H1

Fagron anticipates business acceleration from Q2 and stronger performance in H2

Result Drivers

LATIN AMERICA GROWTH - Latin America delivered 10.4% organic growth at CER, driven by continued success of the Brands strategy in Brazil

M&A CONTRIBUTION - Incremental M&A, including the Pharmavit acquisition, supported topline growth

BRANDS STRATEGY - Positive momentum in the rollout of the Brands strategy contributed to growth, especially in EMEA and Latin America

Company press release: ID:nGNE7CP9Dp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 263.4 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Fagron NV is €28.00, about 26.4% above its April 8 closing price of €22.15

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 14 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)